v3.26.1
Stock-Based Compensation
6 Months Ended
Jun. 30, 2026
Stock-Based Compensation  
Stock-Based Compensation

(11)  Stock-Based Compensation

A summary of stock option activity for the six months ended June 30, 2026 is as follows:

Weighted

Weighted

Average

Average

Exercise

Remaining

Price

Contractual

  ​ ​ ​

Shares

  ​ ​ ​

Per Share

  ​ ​ ​

Term (In Years)

Options outstanding at December 31, 2025

 

9,134,278

$

26.49

7.1

Granted

 

2,588,670

$

33.83

Exercised

 

(41,894)

$

22.30

Canceled

 

(250,328)

$

42.97

Options outstanding at June 30, 2026

 

11,430,726

$

27.80

7.5

Options vested and expected to vest at June 30, 2026

 

11,288,830

$

27.77

7.4

Options exercisable at June 30, 2026

 

6,194,728

$

25.60

6.0

Shares available for grant under the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (as amended, effective as of June 25, 2026) at June 30, 2026

 

3,686,494

The weighted average grant-date fair value of stock options granted during the three and six months ended June 30, 2026 was $20.96 and $20.90, respectively.

The aggregate intrinsic value of stock options vested and expected to vest at June 30, 2026 was $107.2 million. The aggregate intrinsic value of stock options exercisable at June 30, 2026 was $72.5 million. As of June 30, 2026, total compensation cost related to non-vested employee, consultant and non-employee director stock options not yet recognized was approximately $98.5 million, net of estimated forfeitures, which is expected to be recognized as expense over a weighted average period of 3.0 years.

Stock-based compensation expense for the three and six months ended June 30, 2026 and 2025 was recorded as follows:

Three Months Ended June 30, 

Six Months Ended June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

(In thousands)

(In thousands)

Research and development

$

4,588

$

4,882

$

9,235

$

9,467

General and administrative

 

3,820

 

4,309

 

7,696

 

9,040

Total stock-based compensation expense

$

8,408

$

9,191

$

16,931

$

18,507

The fair values of employee, consultant and non-employee director stock options granted during the three and six months ended June 30, 2026 and 2025 were valued using the Black-Scholes option pricing model with the following assumptions:

Three Months Ended June 30, 

Six Months Ended June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Expected stock price volatility

 

63 – 74%

76%

63 – 76%

76 – 81%

Expected option term

 

6.0 Years

6.0 Years

6.0 Years

6.0 Years

Risk-free interest rate

 

4.0 – 4.4%

4.1 – 4.3%

3.8 – 4.4%

4.1 – 4.7%

Expected dividend yield

 

None

None

None

None